N
NEUP
vs
S&P 500
S&P 500
Over the past 12 months, NEUP has underperformed S&P 500, delivering a return of -5% compared to the S&P 500's +27% growth.
Stocks Performance
NEUP vs S&P 500
Performance Gap
NEUP vs S&P 500
Performance By Year
NEUP vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Neuphoria Therapeutics Inc
Glance View
Neuphoria Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Burlington, Massachusetts and currently employs 8 full-time employees. Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company. The firm is focused on developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as needed treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD). BNC210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. Its pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.
